BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline ...
Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~SAN DIEGO, CA / ACCESS Newswire / / , Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a biotechnology company developing ...
BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results